Clinical Trials
Clinical Trial Tracker
Registered trials of peptide compounds, with phase, recruitment status, sponsor, enrollment, and primary endpoints. Search or filter to find any tracked trial.
Showing 3,653 of 3,653 tracked trials
- NCT07382375N/ANot Yet Recruiting
AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection
- Compound
- Thymosin-Alpha-1
- Sponsor
- Nanjing Medical University
- Enrollment
- 300
- Started
- Dec 2027
- NCT07430332Phase 2Not Yet Recruiting
GLP-1 RA for Stage 1 Type 1 Diabetes
- Compound
- Semaglutide
- Sponsor
- Children's Hospital Medical Center, Cincinnati
- Enrollment
- 15
- Started
- Sep 2027
- NCT07754045Phase 2Not Yet Recruiting
Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults
- Compound
- Semaglutide
- Sponsor
- Lumos Pharma
- Enrollment
- 202
- Started
- Feb 2027
- NCT07731256Phase 2Not Yet Recruiting
Semaglutide for Low Back Pain
- Compound
- Semaglutide
- Sponsor
- Washington University School of Medicine
- Enrollment
- 250
- Started
- Feb 2027
- NCT07787936N/ANot Yet Recruiting
GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry
- Compound
- Tirzepatide
- Sponsor
- Miedziowe Centrum Zdrowia SA
- Enrollment
- 150
- Started
- Jan 2027
- NCT06558422Phase 1Not Yet Recruiting
Human Models of Selective Insulin Resistance: Pancreatic Clamp
- Compound
- Octreotide
- Sponsor
- Columbia University
- Enrollment
- 36
- Started
- Jan 2027
- NCT07706361N/ANot Yet Recruiting
Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults
- Compound
- GHK-Cu
- Sponsor
- LifeWave, Inc.
- Enrollment
- 100
- Started
- Jan 2027
- NCT06180616Phase 2Not Yet Recruiting
Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity
- Compound
- Tirzepatide
- Sponsor
- Royal North Shore Hospital
- Enrollment
- 40
- Started
- Dec 2026
- NCT07790861Phase 3Not Yet Recruiting
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
- Compound
- Orforglipron
- Sponsor
- Eli Lilly and Company
- Enrollment
- 192
- Started
- Dec 2026
- NCT07468552Phase 2Not Yet Recruiting
Trial of Tirzepatide for the Treatment of Cannabis Use Disorder
- Compound
- Tirzepatide
- Sponsor
- National Institute on Drug Abuse (NIDA)
- Enrollment
- 100
- Started
- Nov 2026
- NCT07027969Phase 4Not Yet Recruiting
Metabolic Surgery for Atrial Fibrillation Elimination
- Compound
- Tirzepatide
- Sponsor
- Ali Aminian
- Enrollment
- 100
- Started
- Nov 2026
- NCT07349641Phase 2Not Yet Recruiting
A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer
- Compound
- Tirzepatide
- Sponsor
- National Cancer Institute (NCI)
- Enrollment
- 55
- Started
- Nov 2026
- NCT07609160N/ANot Yet Recruiting
Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals
- Compound
- Tirzepatide
- Sponsor
- Acibadem University
- Enrollment
- 108
- Started
- Nov 2026
- NCT06546384N/ANot Yet Recruiting
GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease
- Compound
- Semaglutide
- Sponsor
- Insel Gruppe AG, University Hospital Bern
- Enrollment
- 64
- Started
- Nov 2026
- NCT07781150Phase 2Not Yet Recruiting
Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer
- Compound
- Mazdutide
- Sponsor
- Tongji Hospital
- Enrollment
- 128
- Started
- Nov 2026
- NCT07729332Phase 4Not Yet Recruiting
Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation
- Compound
- Orforglipron
- Sponsor
- Massachusetts General Hospital
- Enrollment
- 60
- Started
- Nov 2026
- NCT07772960Phase 1Not Yet Recruiting
Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes
- Compound
- Semaglutide
- Sponsor
- Yale University
- Enrollment
- 90
- Started
- Oct 2026
- NCT06977438Phase 4Not Yet Recruiting
GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward
- Compound
- Semaglutide
- Sponsor
- University of Minnesota
- Enrollment
- 1,020
- Started
- Oct 2026
- NCT07739537Phase 4Not Yet Recruiting
PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses
- Compound
- Orforglipron
- Sponsor
- Massachusetts General Hospital
- Enrollment
- 100
- Started
- Oct 2026
- NCT07782359Phase 1Not Yet Recruiting
Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib
- Compound
- Tirzepatide
- Sponsor
- University of Chicago
- Enrollment
- 30
- Started
- Oct 2026
- NCT07758231Phase 1Not Yet Recruiting
Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics
- Compound
- Tirzepatide
- Sponsor
- University of Wisconsin, Madison
- Enrollment
- 5
- Started
- Oct 2026
- NCT07677891Phase 2Not Yet Recruiting
Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus
- Compound
- Dulaglutide
- Sponsor
- ProGen. Co., Ltd.
- Enrollment
- 60
- Started
- Oct 2026
- NCT07767552N/ANot Yet Recruiting
Mazdutide for Remission of Type 2 Diabetes: Multicentre, Double Blind, Randomised, Placebo Controlled Trial
- Compound
- Mazdutide
- Sponsor
- Yanbing Li
- Enrollment
- 249
- Started
- Sep 2026
- NCT07589686Phase 2Not Yet Recruiting
A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight
- Compound
- Petrelintide
- Sponsor
- Hoffmann-La Roche
- Enrollment
- 486
- Started
- Sep 2026
- NCT07668414Phase 3Not Yet Recruiting
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
- Compound
- Semaglutide
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 650
- Started
- Sep 2026
- NCT07340619Phase 2Not Yet Recruiting
Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.
- Compound
- Gonadorelin
- Sponsor
- UNICANCER
- Enrollment
- 51
- Started
- Sep 2026
- NCT07734870Phase 2Not Yet Recruiting
Tirzepatide for Treatment of CCCA
- Compound
- Tirzepatide
- Sponsor
- Johns Hopkins University
- Enrollment
- 20
- Started
- Sep 2026
- NCT07713992N/ANot Yet Recruiting
Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide
- Compound
- Semaglutide
- Sponsor
- Tianjin Medical University
- Enrollment
- 72
- Started
- Sep 2026
- NCT07728812N/ANot Yet Recruiting
Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy
- Compound
- Tirzepatide
- Sponsor
- Phenomix Sciences
- Enrollment
- 424
- Started
- Sep 2026
- NCT07715929Phase 4Not Yet Recruiting
Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients
- Compound
- Tirzepatide
- Sponsor
- Yunlong Wang
- Enrollment
- 710
- Started
- Sep 2026